INITIO Nuclear Medicine Diagnostics/Therapeutics/Clinical Research CANADA
INITIO transforms patient care creating accessibility & affordability to Nuclear Medicine Diagnostics & Therapy via expanding community capacity.
INITIO transforms patient care by creating Accessibility & Affordability to Nuclear Medicine Diagnostics & Targeted Therapy for Canadians, Americans, and International patients around the globe through expanding the available capacity within patient communities. Providing immediate PET/CT diagnostic imaging to assist with diagnoses and assessment for both cancer and non-cancerous conditions. These include (but not limited to) all Cancer, Prostate Cancer, Neuroendocrine Disease, Inflammatory Disease, Neurodegenerative Disorders as well as Alzheimer’s and Parkinson’s Disease, Neurodegeneration, and Cognitive Impairment after traumatic brain injury. (INITIO presently utilizes Ga-68 PSMA, Ga-68 DOTATATE, FDG tracers) INITIO’s Therapeutic Centres provides prostate-specific membrane antigen (PSMA) targeted radiation treatment proven to damage and destroy prostate cancer cells over time, significantly improving prostate cancer survival rates, quality of life, and extending length of progression. (Utilizing Lutetium-177). Scans completed the same week as referral with exceptional low costs.
Physician or nurse practitioner requisition required. Forms available online at initiomedical.ca Headquartered in Burnaby, BC expanding across Canada.
Brands: INITIO is Western Canada's only private Nuclear Medicine facility offering Diagnostics, Therapeutics and Clinical Research. INITIO's PET/CT scanner is the GE Healthcare Discovery IQ Gen 2, the most widely used PET/CT system around the globe providing INITIO the ability for significantly reduced tracer dosing and enhanced accurate staging of disease meaning higher confidence in the next treatment steps.